Pipeline & Platform


PT003, Pearl’s lead combination new drug product candidate, is composed of the long-acting muscarinic antagonist (LAMA) glycopyrronium, and the long acting β2-agonist (LABA) formoterol fumarate, administered twice daily (BID) from an HFA-MDI. PT003 is the only approved LAMA/LABA combination product in a HFA MDI dosage formulation.

PT001 / PT005

PT001 and PT005 are Pearl's monotherapy Co-SuspensionTM Delivery Technology candidates. PT001 contains the long-acting muscarinic antagonist (LAMA), glycopyrronium. PT005 contains the long acting β2-agonist (LABA) formoterol fumarate. Glycopyrronium and formoterol fumarate are highly potent bronchodilators under evaluation to treat patients with COPD. By leveraging the flexibility of Pearl’s Co-SuspensionTM Delivery Technology platform, the Company has been able to evaluate doses of these monotherapy products as low as 600 nanograms in patients with COPD.

For more Pearl milestones, please click here.

1 - Formoterol fumarate has been approved for use in several forms for the treatment of patients with COPD, including Foradil® Aerolizer® (formoterol fumarate inhalation powder) by Schering-Plough and Novartis, Oxis® turbohaler® by AstraZeneca and SYMBICORT® (budesonide/formoterol fumarate dihydrate) by AstraZeneca.